Ruxolitinib(Jakafi). This is a recently approved drug for acute GVHD for ages 12 and over. It targets enzymes called JAKs (Janus-associated kinases) that play a role in developing cancer. Monoclonal antibodiesare biologic, or manmade, drugs that target specific cells involved in GVHD, including...